Adding up the healthcare costs when estrogen therapy is avoided after hysterectomy

Affiliations

Editorial

Philip M Sarrel. Menopause. 2020 Jun.

. 2020 Jun;27(6):625-627.

doi: 10.1097/GME.0000000000001548.

No abstract available

Comment on

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups.
Donneyong MM, Chang TJ, Roth JA, Guilds M, Ankrah D, Najafzadeh M, Xu WY, Chlebowski RT, Margolis K, Manson JE. Donneyong MM, et al. Menopause. 2020 Jun;27(6):632-639. doi: 10.1097/GME.0000000000001517. Menopause. 2020. PMID: 32132440 Free PMC article.

1. Sarrel P, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause 2015; 22:260–266.
1. Kleinman NL, Rohrbacker NJ, Bushmakin AG, Whiteley J, Lynch WD, Shah SN. Direct and indirect costs of women diagnosed with menopause symptoms. J Occup Environ Med 2013; 55:465–470.
1. Whiteley J, Wagner J-S, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause 2013; 20:518–524.
1. Tang WY, Grothe D, Keshishian A, Morgenstern D, Haider S. Pharmacoeconomic and associated cost savings among women who were prescribed systemic conjugated equine estrogen therapy compared to those without menopausal therapy. Menopause 2018; 25:493–499.
1. Salpeter S, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger menopausal women. Am J Med 2009; 122:1016–1022.